Cargando…

Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

BACKGROUND: Lung cancer is the leading cause of cancer deaths worldwide in both men and women, and non-small cell lung cancer (NSCLC) accounts for the majority (~ 85%) of lung cancers. This post-marketing surveillance (PMS) study aimed to evaluate the safety of Pemetrexed (Alvopem(®), NanoAlvand, Ir...

Descripción completa

Detalles Bibliográficos
Autores principales: Seifi, Sharareh, Salimi, Babak, Monfared, Zahra Esfahani, Sabahi, Cyrus, Kafi, Hamidreza, Khosravi, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878795/
https://www.ncbi.nlm.nih.gov/pubmed/36698207
http://dx.doi.org/10.1186/s40545-023-00524-5
_version_ 1784878565501698048
author Seifi, Sharareh
Salimi, Babak
Monfared, Zahra Esfahani
Sabahi, Cyrus
Kafi, Hamidreza
Khosravi, Adnan
author_facet Seifi, Sharareh
Salimi, Babak
Monfared, Zahra Esfahani
Sabahi, Cyrus
Kafi, Hamidreza
Khosravi, Adnan
author_sort Seifi, Sharareh
collection PubMed
description BACKGROUND: Lung cancer is the leading cause of cancer deaths worldwide in both men and women, and non-small cell lung cancer (NSCLC) accounts for the majority (~ 85%) of lung cancers. This post-marketing surveillance (PMS) study aimed to evaluate the safety of Pemetrexed (Alvopem(®), NanoAlvand, Iran) in Iranian patients with lung cancer or mesothelioma. METHODS: The present study is an observational, single-center, open-label, and post-authorization study. All eligible non-squamous NSCLC and malignant pleural mesothelioma (MPM) patients who received pemetrexed based on the physicians’ decision, were enrolled. RESULTS: A total of 199 patients with non-squamous NSCLC [186 patients (93.47%) or MPM (12 patients (6.03%)] were enrolled from March 2016 to February 2020. The most common reported adverse event (AE) was anemia (89.39%), followed by neutropenia (28.79%) and leukopenia (24.75%). The most important grade 3 AEs were anemia and neutropenia, with the incidence rate of 3.54% and 7.58%, respectively. No grade 4 AEs were reported. Moreover, the results of our study showed negative statistically significant correlations between patients’ age and mean neutrophil count (r = − 0.17; P = 0.0156) and hemoglobin (r = − 0.16; P = 0.0201) in all six visits. CONCLUSIONS: The results of this open-label, observational PMS showed that Pemetrexed (Alvopem(®)) is safe in patients with non-squamous NSCLC patients receiving pemetrexed-containing regimens. Trial registration: The trial was registered at ClinicalTrials.gov (NCT04843007) in April 13th, 2021.
format Online
Article
Text
id pubmed-9878795
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98787952023-01-27 Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance Seifi, Sharareh Salimi, Babak Monfared, Zahra Esfahani Sabahi, Cyrus Kafi, Hamidreza Khosravi, Adnan J Pharm Policy Pract Research BACKGROUND: Lung cancer is the leading cause of cancer deaths worldwide in both men and women, and non-small cell lung cancer (NSCLC) accounts for the majority (~ 85%) of lung cancers. This post-marketing surveillance (PMS) study aimed to evaluate the safety of Pemetrexed (Alvopem(®), NanoAlvand, Iran) in Iranian patients with lung cancer or mesothelioma. METHODS: The present study is an observational, single-center, open-label, and post-authorization study. All eligible non-squamous NSCLC and malignant pleural mesothelioma (MPM) patients who received pemetrexed based on the physicians’ decision, were enrolled. RESULTS: A total of 199 patients with non-squamous NSCLC [186 patients (93.47%) or MPM (12 patients (6.03%)] were enrolled from March 2016 to February 2020. The most common reported adverse event (AE) was anemia (89.39%), followed by neutropenia (28.79%) and leukopenia (24.75%). The most important grade 3 AEs were anemia and neutropenia, with the incidence rate of 3.54% and 7.58%, respectively. No grade 4 AEs were reported. Moreover, the results of our study showed negative statistically significant correlations between patients’ age and mean neutrophil count (r = − 0.17; P = 0.0156) and hemoglobin (r = − 0.16; P = 0.0201) in all six visits. CONCLUSIONS: The results of this open-label, observational PMS showed that Pemetrexed (Alvopem(®)) is safe in patients with non-squamous NSCLC patients receiving pemetrexed-containing regimens. Trial registration: The trial was registered at ClinicalTrials.gov (NCT04843007) in April 13th, 2021. BioMed Central 2023-01-25 /pmc/articles/PMC9878795/ /pubmed/36698207 http://dx.doi.org/10.1186/s40545-023-00524-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Seifi, Sharareh
Salimi, Babak
Monfared, Zahra Esfahani
Sabahi, Cyrus
Kafi, Hamidreza
Khosravi, Adnan
Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
title Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
title_full Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
title_fullStr Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
title_full_unstemmed Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
title_short Alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
title_sort alvopem(®) (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878795/
https://www.ncbi.nlm.nih.gov/pubmed/36698207
http://dx.doi.org/10.1186/s40545-023-00524-5
work_keys_str_mv AT seifisharareh alvopempemetrexedsafetyassessmentinpatientswithnonsmallcelllungcancerormalignantpleuralmesotheliomaapostmarketingsurveillance
AT salimibabak alvopempemetrexedsafetyassessmentinpatientswithnonsmallcelllungcancerormalignantpleuralmesotheliomaapostmarketingsurveillance
AT monfaredzahraesfahani alvopempemetrexedsafetyassessmentinpatientswithnonsmallcelllungcancerormalignantpleuralmesotheliomaapostmarketingsurveillance
AT sabahicyrus alvopempemetrexedsafetyassessmentinpatientswithnonsmallcelllungcancerormalignantpleuralmesotheliomaapostmarketingsurveillance
AT kafihamidreza alvopempemetrexedsafetyassessmentinpatientswithnonsmallcelllungcancerormalignantpleuralmesotheliomaapostmarketingsurveillance
AT khosraviadnan alvopempemetrexedsafetyassessmentinpatientswithnonsmallcelllungcancerormalignantpleuralmesotheliomaapostmarketingsurveillance